Home > Insider Trading > Filing (0000921895-19-002391)

Filing Details

Accession Number:: 0000921895-19-002391
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-10 18:00:58
Reporting Period:: 2019-09-06

Accepted Time:: 2019-09-10 18:00:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1583648	Pieris Pharmaceuticals Inc.	PIRS	Investment Advice (6282)	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
918923	P L Fund Value Biotechnology	44 Montgomery Street 40Th Fl San Francisco CA 94104	No	No	No	Yes
1055947	P/Il L Partners Bvf	44 Montgomery Street 40Th Fl San Francisco CA 94104	No	No	Yes	No
1056807	Bvf Inc/Il	44 Montgomery Street 40Th Fl San Francisco CA 94104	No	No	Yes	No
1102444	Biotechnology Value Fund Ii Lp	44 Montgomery Street 40Th Fl San Francisco CA 94104	No	No	No	Yes
1233840	N Mark Lampert	44 Montgomery Street 40Th Fl San Francisco CA 94104	No	No	Yes	No
1660683	Biotechnology Value Trading Fund Os Lp	P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104	No	No	No	Yes
1660684	Ltd. Os Partners Bvf	P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.001 Par Value	Disposition	2019-09-06	23,152	$4.50	2,385,055	No	4	S	Direct
Common Stock, $0.001 Par Value	Disposition	2019-09-06	25,720	$4.50	2,233,074	No	4	S	Direct
Common Stock, $0.001 Par Value	Disposition	2019-09-06	1,128	$4.50	314,139	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Amount	Remaning Holdings	Nature of Ownership
Common Stock, $0.001 Par Value	Series A Convertible Preferred Stock, $0.001 par value	$0.00	1,567,000	1,567	Direct
Common Stock, $0.001 Par Value	Series A Convertible Preferred Stock, $0.001 par value	$0.00	1,021,000	1,021	Direct
Common Stock, $0.001 Par Value	Series A Convertible Preferred Stock, $0.001 par value	$0.00	319,000	319	Direct
Common Stock, $0.001 Par Value	Series B Convertible Preferred Stock, $0.001 par value	$0.00	2,573,000	2,573	Direct
Common Stock, $0.001 Par Value	Series B Convertible Preferred Stock, $0.001 par value	$0.00	2,143,000	2,143	Direct
Common Stock, $0.001 Par Value	Series B Convertible Preferred Stock, $0.001 par value	$0.00	284,000	284	Direct
Common Stock, $0.001 Par Value	Tranche A Warrants	$2.00	854,800	854,800	Direct
Common Stock, $0.001 Par Value	Tranche A Warrants	$2.00	560,400	560,400	Direct
Common Stock, $0.001 Par Value	Tranche A Warrants	$2.00	167,600	167,600	Direct
Common Stock, $0.001 Par Value	Tranche B Warrants	$3.00	427,400	427,400	Direct
Common Stock, $0.001 Par Value	Tranche B Warrants	$3.00	280,200	280,200	Direct
Common Stock, $0.001 Par Value	Tranche B Warrants	$3.00	83,800	83,800	Direct

Amount	Remaning Holdings	Nature of Ownership
1,567,000	1,567	Direct
1,021,000	1,021	Direct
319,000	319	Direct
2,573,000	2,573	Direct
2,143,000	2,143	Direct
284,000	284	Direct
854,800	854,800	Direct
560,400	560,400	Direct
167,600	167,600	Direct
427,400	427,400	Direct
280,200	280,200	Direct
83,800	83,800	Direct

Footnotes

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously owned in the aggregate more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
The Reporting Persons hold 2,907 shares of Series A Convertible Preferred Stock, (the "Series A Preferred Stock") convertible for an aggregate of 2,907,000 shares of Common Stock. Each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock. The Series A Preferred Stock is convertible at any time, at the holder's election, except that the Series A Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), more than 9.99% of the number of shares of Common Stock then issued and outstanding.
The Reporting Persons hold 5,000 shares of Series B Convertible Preferred Stock, (the "Series B Preferred Stock") convertible for an aggregate of 5,000,000 shares of Common Stock. Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock. The Series B Preferred Stock is convertible at any time, at the holder's election, except that the Series B Preferred Stock may not be converted if, after such conversion, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding.
The Reporting Persons hold 1,582,800 Tranche A Warrants (the "A Warrants") exercisable for an aggregate of 1,582,800 shares of Common Stock. The A Warrants have an exercise price of $2.00 per share and expire on June 8, 2021. The A Warrants are exercisable at any time, at the holder's election, except that the A Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding.
The Reporting Persons hold 791,400 Tranche B Warrants (the "B Warrants") exercisable for an aggregate of 791,400 shares of Common Stock. The B Warrants have an exercise price of $3.00 per share and expire on June 8, 2021. The B Warrants are exercisable at any time, at the holder's election, except that the B Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of Common Stock then issued and outstanding.